Maze Therapeutics, Inc. (MAZE): who owns it and who trades it
As of Nov 16, 2026, MAZE insiders reported 100 open-market sales worth $25M and no purchases in the last 12 months, with 91% of the sale value made under pre-set 10b5-1 plans. The largest seller was Harold Bernstein (President), with $9.5M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Maze Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MAZE
162 funds and institutions reported MAZE shares worth $1.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 9.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.03M | 9.09% | $150M | +10% |
| Trv Gp Iv, LLC | 4.47M | 8.08% | $134M | No change |
| ARCH Venture Management, LLC | 4.12M | 7.44% | $123M | No change |
| Deep Track Capital, LP | 3.73M | 6.74% | $111M | +7% |
| BlackRock, Inc. | 3.50M | 6.33% | $105M | +36% |
| Jupiter Topco LLC | 3.41M | 6.16% | $102M | – |
| T. Rowe Price Investment Management, Inc. | 2.60M | 4.70% | $77.7M | – |
| Logos Global Management LP | 1.94M | 3.50% | $57.7M | +57% |
| Vanguard Capital Management LLC | 1.78M | 3.21% | $53.1M | +24% |
| A16z Capital Management, L.L.C. | 1.70M | 3.08% | $50.8M | No change |
| Venrock Adviser, LLC | 1.60M | 2.89% | $47.8M | No change |
| Alphabet Inc. | 1.39M | 2.51% | $41.4M | No change |
| Braidwell LP | 1.14M | 2.06% | $34M | – |
| Farallon Capital Management, L.l.c. | 1.11M | 2.00% | $33.1M | +197% |
| FMR LLC (Fidelity) | 1.06M | 1.91% | $31.5M | +22% |
| General Catalyst Group Management, LLC | 1.04M | 1.87% | $30.9M | No change |
| State Street Corp | 997,533 | 1.80% | $29.8M | +57% |
| JPMorgan Chase & Co | 964,011 | 1.74% | $28M | – |
| Driehaus Capital Management LLC | 954,886 | 1.73% | $28.5M | +50% |
| Trv Gp V, LLC | 950,800 | 1.72% | $28.4M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MAZE insiders reported $0 of open-market purchases and $25M of sales. 91% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Jason V Coloma | CEO | Sale plan | 2,257 | $30.12 | $68K | Form 4 |
| Nov 2, 2026 | Jason V Coloma | CEO | Sale plan | 336 | $30.91 | $10.4K | Form 4 |
| Nov 2, 2026 | Jason V Coloma | CEO | Sale plan | 26,563 | $30.09 | $799K | Form 4 |
| Nov 2, 2026 | Jason V Coloma | CEO | Sale plan | 5,345 | $31.05 | $166K | Form 4 |
| Oct 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $32.07 | $241K | Form 4 |
| Oct 1, 2026 | Harold Bernstein | President | Sale plan | 16,141 | $26.93 | $435K | Form 4 |
| Oct 1, 2026 | Jason V Coloma | CEO | Sale plan | 2,593 | $27.02 | $70.1K | Form 4 |
| Oct 1, 2026 | Jason V Coloma | CEO | Sale plan | 31,908 | $27.02 | $862K | Form 4 |
| Sep 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $27.06 | $203K | Form 4 |
| Sep 4, 2026 | Harold Bernstein | President | Sale plan | 9,705 | $26.22 | $254K | Form 4 |
| Sep 3, 2026 | Phillips Courtney | GC and Corp. Secretary | Sale | 1,990 | $26.01 | $51.8K | Form 4 |
| Sep 3, 2026 | Phillips Courtney | GC and Corp. Secretary | Sale | 22 | $25.78 | $567 | Form 4 |
| Sep 3, 2026 | Atul Dandekar | CSBO | Sale | 3,207 | $26.01 | $83.4K | Form 4 |
| Sep 3, 2026 | Atul Dandekar | CSBO | Sale | 36 | $25.81 | $929 | Form 4 |
| Sep 3, 2026 | Jason V Coloma | CEO | Sale | 129 | $25.77 | $3.3K | Form 4 |
| Sep 3, 2026 | Jason V Coloma | CEO | Sale | 11,282 | $26.01 | $293K | Form 4 |
| Sep 3, 2026 | Harold Bernstein | President | Sale | 59 | $25.78 | $1.5K | Form 4 |
| Sep 3, 2026 | Harold Bernstein | President | Sale | 5,130 | $26.01 | $133K | Form 4 |
| Sep 2, 2026 | Phillips Courtney | GC and Corp. Secretary | Sale | 243 | $27.12 | $6.6K | Form 4 |
| Sep 2, 2026 | Phillips Courtney | GC and Corp. Secretary | Sale | 1,738 | $26.38 | $45.8K | Form 4 |
| Sep 2, 2026 | Atul Dandekar | CSBO | Sale | 2,800 | $26.38 | $73.9K | Form 4 |
| Sep 2, 2026 | Atul Dandekar | CSBO | Sale | 391 | $27.12 | $10.6K | Form 4 |
| Sep 2, 2026 | Jason V Coloma | CEO | Sale | 1,375 | $27.12 | $37.3K | Form 4 |
| Sep 2, 2026 | Jason V Coloma | CEO | Sale | 9,852 | $26.38 | $260K | Form 4 |
| Sep 2, 2026 | Harold Bernstein | President | Sale | 625 | $27.12 | $16.9K | Form 4 |
| Sep 2, 2026 | Harold Bernstein | President | Sale | 4,481 | $26.38 | $118K | Form 4 |
| Sep 1, 2026 | Jason V Coloma | CEO | Sale plan | 2,593 | $26.31 | $68.2K | Form 4 |
| Sep 1, 2026 | Jason V Coloma | CEO | Sale plan | 31,908 | $26.29 | $839K | Form 4 |
| Sep 1, 2026 | Harold Bernstein | President | Sale plan | 16,141 | $26.36 | $425K | Form 4 |
| Aug 28, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $27.58 | $207K | Form 4 |
| Aug 13, 2026 | Harold Bernstein | President | Sale plan | 16,142 | $27.61 | $446K | Form 4 |
| Aug 3, 2026 | Jason V Coloma | CEO | Sale plan | 2,439 | $26.71 | $65.1K | Form 4 |
| Aug 3, 2026 | Jason V Coloma | CEO | Sale plan | 154 | $27.09 | $4.2K | Form 4 |
| Aug 3, 2026 | Jason V Coloma | CEO | Sale plan | 30,304 | $26.71 | $809K | Form 4 |
| Aug 3, 2026 | Jason V Coloma | CEO | Sale plan | 1,604 | $27.09 | $43.5K | Form 4 |
| Jul 29, 2026 | Atul Dandekar | CSBO | Sale plan | 400 | $27.89 | $11.2K | Form 4 |
| Jul 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,100 | $27.31 | $194K | Form 4 |
| Jul 1, 2026 | Harold Bernstein | President | Sale plan | 1,200 | $30.34 | $36.4K | Form 4 |
| Jul 1, 2026 | Harold Bernstein | President | Sale plan | 13,409 | $29.87 | $401K | Form 4 |
| Jul 1, 2026 | Jason V Coloma | CEO | Sale plan | 1,597 | $30.44 | $48.6K | Form 4 |
| Jul 1, 2026 | Jason V Coloma | CEO | Sale plan | 2,593 | $29.98 | $77.7K | Form 4 |
| Jul 1, 2026 | Jason V Coloma | CEO | Sale plan | 30,311 | $29.95 | $908K | Form 4 |
| Jun 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $28.02 | $210K | Form 4 |
| Jun 23, 2026 | Jason V Coloma | CEO | Sale plan | 23,865 | $26.05 | $622K | Form 4 |
| Jun 22, 2026 | Jason V Coloma | CEO | Sale plan | 1,953 | $26.00 | $50.8K | Form 4 |
| Jun 22, 2026 | Jason V Coloma | CEO | Sale plan | 2,040 | $26.00 | $53K | Form 4 |
| Jun 1, 2026 | Jason V Coloma | CEO | Sale plan | 6,090 | $26.20 | $160K | Form 4 |
| Jun 1, 2026 | Jason V Coloma | CEO | Sale plan | 553 | $26.24 | $14.5K | Form 4 |
| Jun 1, 2026 | Harold Bernstein | President | Sale plan | 1,600 | $26.36 | $42.2K | Form 4 |
| Jun 1, 2026 | Harold Bernstein | President | Sale plan | 13,253 | $25.57 | $339K | Form 4 |
| May 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $26.34 | $198K | Form 4 |
| May 26, 2026 | Jason V Coloma | CEO | Sale plan | 25,582 | $26.02 | $666K | Form 4 |
| May 22, 2026 | Jason V Coloma | CEO | Sale plan | 4,504 | $26.00 | $117K | Form 4 |
| May 22, 2026 | Jason V Coloma | CEO | Sale plan | 2,478 | $26.00 | $64.4K | Form 4 |
| May 15, 2026 | Jason V Coloma | CEO | Sale plan | 116 | $26.00 | $3K | Form 4 |
| May 15, 2026 | Jason V Coloma | CEO | Sale plan | 1,822 | $26.00 | $47.4K | Form 4 |
| May 14, 2026 | Harold Bernstein | President | Sale plan | 15,000 | $26.22 | $393K | Form 4 |
| Apr 29, 2026 | Atul Dandekar | CSBO | Sale plan | 7,500 | $25.37 | $190K | Form 4 |
| Apr 1, 2026 | Harold Bernstein | President | Sale plan | 11,352 | $29.24 | $332K | Form 4 |
| Apr 1, 2026 | Harold Bernstein | President | Sale plan | 3,348 | $30.06 | $101K | Form 4 |
| Apr 1, 2026 | Harold Bernstein | President | Sale plan | 300 | $31.07 | $9.3K | Form 4 |
| Apr 1, 2026 | Amy Bachrodt | Vice president | Sale plan | 300 | $30.34 | $9.1K | Form 4 |
| Apr 1, 2026 | Amy Bachrodt | Vice president | Sale plan | 2,200 | $29.32 | $64.5K | Form 4 |
| Mar 30, 2026 | Atul Dandekar | CSBO | Sale plan | 6,710 | $29.26 | $196K | Form 4 |
| Mar 30, 2026 | Atul Dandekar | CSBO | Sale plan | 790 | $30.02 | $23.7K | Form 4 |
| Mar 20, 2026 | Harold Bernstein | President | Sale plan | 6,161 | $48.20 | $297K | Form 4 |
| Mar 20, 2026 | Harold Bernstein | President | Sale plan | 3,795 | $49.32 | $187K | Form 4 |
| Mar 20, 2026 | Harold Bernstein | President | Sale plan | 5,044 | $50.02 | $252K | Form 4 |
| Mar 10, 2026 | Harold Bernstein | President | Sale plan | 348 | $51.02 | $17.8K | Form 4 |
| Mar 10, 2026 | Harold Bernstein | President | Sale plan | 29,652 | $50.45 | $1.5M | Form 4 |
| Mar 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 1,300 | $44.44 | $57.8K | Form 4 |
| Mar 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 3,700 | $45.47 | $168K | Form 4 |
| Feb 27, 2026 | Atul Dandekar | CSBO | Sale plan | 3,761 | $45.72 | $172K | Form 4 |
| Feb 27, 2026 | Atul Dandekar | CSBO | Sale plan | 3,739 | $45.13 | $169K | Form 4 |
| Feb 2, 2026 | Harold Bernstein | President | Sale plan | 600 | $44.21 | $26.5K | Form 4 |
| Feb 2, 2026 | Harold Bernstein | President | Sale plan | 8,364 | $45.89 | $384K | Form 4 |
| Feb 2, 2026 | Harold Bernstein | President | Sale plan | 100 | $47.23 | $4.7K | Form 4 |
| Feb 2, 2026 | Harold Bernstein | President | Sale plan | 5,936 | $46.37 | $275K | Form 4 |
| Feb 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 736 | $46.63 | $34.3K | Form 4 |
| Feb 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 4,064 | $46.03 | $187K | Form 4 |
| Feb 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 200 | $44.15 | $8.8K | Form 4 |
| Jan 29, 2026 | Atul Dandekar | CSBO | Sale plan | 1,200 | $43.18 | $51.8K | Form 4 |
| Jan 29, 2026 | Atul Dandekar | CSBO | Sale plan | 2,800 | $45.01 | $126K | Form 4 |
| Jan 29, 2026 | Atul Dandekar | CSBO | Sale plan | 3,500 | $44.04 | $154K | Form 4 |
| Jan 22, 2026 | Amy Bachrodt | Vice president | Sale plan | 5,000 | $45.52 | $228K | Form 4 |
| Jan 7, 2026 | Harold Bernstein | President | Sale plan | 25,156 | $40.20 | $1M | Form 4 |
| Jan 7, 2026 | Catherine A. Sohn | Director | Sale | 26,920 | $39.11 | $1.1M | Form 4 |
| Jan 6, 2026 | Catherine A. Sohn | Director | Sale | 2,493 | $38.62 | $96.3K | Form 4 |
| Jan 5, 2026 | Harold Bernstein | President | Sale plan | 412 | $40.00 | $16.5K | Form 4 |
| Jan 2, 2026 | Harold Bernstein | President | Sale plan | 4,432 | $40.43 | $179K | Form 4 |
| Jan 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 2,405 | $38.70 | $93.1K | Form 4 |
| Jan 2, 2026 | Amy Bachrodt | Vice president | Sale plan | 2,595 | $39.57 | $103K | Form 4 |
| Dec 30, 2025 | Atul Dandekar | CSBO | Sale plan | 100 | $40.36 | $4K | Form 4 |
| Dec 30, 2025 | Amy Bachrodt | Vice president | Sale plan | 5,000 | $40.08 | $200K | Form 4 |
| Dec 29, 2025 | Atul Dandekar | CSBO | Sale plan | 6,035 | $41.13 | $248K | Form 4 |
| Dec 29, 2025 | Atul Dandekar | CSBO | Sale plan | 66,365 | $40.51 | $2.7M | Form 4 |
| Dec 29, 2025 | Harold Bernstein | President | Sale plan | 17,200 | $40.93 | $704K | Form 4 |
| Dec 29, 2025 | Harold Bernstein | President | Sale plan | 27,800 | $40.34 | $1.1M | Form 4 |
| Dec 29, 2025 | Amy Bachrodt | Vice president | Sale plan | 600 | $41.16 | $24.7K | Form 4 |
| Dec 29, 2025 | Amy Bachrodt | Vice president | Sale plan | 9,400 | $40.54 | $381K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Harold Bernstein | President, R&D & CMO | – | $9.5M | Oct 1, 2026 |
| Jason V Coloma | Chief Executive Officer, Director | – | $7.2M | Nov 2, 2026 |
| Atul Dandekar | CSBO | – | $5.5M | Oct 29, 2026 |
| Amy Bachrodt | SVP, Finance | – | $1.6M | Apr 1, 2026 |
| Catherine A. Sohn | Director | – | $1.1M | Jan 7, 2026 |
| Phillips Courtney | GC and Corp. Secretary | – | $105K | Sep 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MAZE short interest
High short interest. 12.0% of MAZE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 69%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.68M MAZE shares were sold short, 12.0% of the shares outstanding, down 11.2% from the report before. At the average daily volume of 763,468 shares, buying them all back would take about 8.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.68M | 12.03% | -11% | 763,468 | 8.8 |
| Oct 15, 2026 | 7.53M | 13.55% | +15% | 745,712 | 10.1 |
| Sep 30, 2026 | 6.57M | 11.82% | +16% | 1.08M | 6.1 |
| Sep 15, 2026 | 5.68M | 10.22% | -4% | 546,179 | 10.4 |
| Aug 31, 2026 | 5.92M | 10.65% | -1% | 368,764 | 16.1 |
| Aug 14, 2026 | 5.99M | 10.78% | +5% | 370,295 | 16.2 |
| Jul 31, 2026 | 5.68M | 10.26% | +3% | 357,598 | 15.9 |
| Jul 15, 2026 | 5.53M | 9.98% | No change | 651,947 | 8.5 |
| Jun 30, 2026 | 5.53M | 9.99% | +36% | 1.03M | 5.4 |
| Jun 15, 2026 | 4.06M | 7.33% | +4% | 527,440 | 7.7 |
| May 29, 2026 | 3.90M | 7.04% | -1% | 442,125 | 8.8 |
| May 15, 2026 | 3.95M | 7.14% | -9% | 533,249 | 7.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Maze Therapeutics company events
Maze Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 16, 2026AgreementThe information contained below under Item 3.02 is hereby incorporated by reference in response to this Item 1.01 of Form 8-K. Item 3.02. Filing
- Aug 17, 2026LeadershipThe Board of Directors of Maze Therapeutics, Inc. appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026. Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 22, 2026LeadershipAmy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc., effective June 1, 2026. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 22, 2026AnnouncementMaze Therapeutics, Inc., a Delaware corporation, entered into an underwriting agreement with Leerink Partners LLC as sole underwriter, pursuant to which the Company agreed to issue and sell an aggregate of (a) 5,540,000 shares of its common stock and (b) pre-funded warrants to purchase 850,000… Filing
- Mar 25, 2026LeadershipThe Board of Directors of the Company appointed Neil Kumar as a Class I director, effective March 27, 2026. Filing
- Feb 4, 2026AgreementMaze Therapeutics, Inc. entered into that certain Loan and Security Agreement, by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Maze Therapeutics financials
Famous investors that hold MAZE
1 of the 50 well-known investors we track reported holding MAZE in their latest 13F filing. The largest position is Ken Griffin's, worth $42.9M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.58M | $42.9M | 0.0% | +85% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MAZE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Third Rock Ventures IV, L.P. | 13G/A | 6.7% |
| Nov 16, 2026 | Third Rock Ventures IV, L.P. | 13G/A | 6.7% |
Questions about Maze Therapeutics, Inc. (MAZE) stock
Who owns the most MAZE stock?
The largest reported owner of Maze Therapeutics, Inc. (MAZE) is Frazier Life Sciences Management, L.P., with 9.1% of the company. In total, 162 funds and institutions reported holding MAZE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MAZE insiders buying or selling?
In the last 12 months, MAZE insiders reported no open-market purchases and 100 sales worth $25M. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in MAZE?
As of Oct 30, 2026, 6.68M MAZE shares were sold short, 12.0% of the shares outstanding, down 11.2% from the report before. At the average daily volume of 763,468 shares, buying them all back would take about 8.8 trading days (days to cover). See the history.
Which famous investors hold MAZE?
1 of the 50 well-known investors we track reported MAZE in their latest 13F filing, including Ken Griffin. The largest position is worth $42.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.